<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000116</url>
  </required_header>
  <id_info>
    <org_study_id>NEI-12</org_study_id>
    <nct_id>NCT00000116</nct_id>
  </id_info>
  <brief_title>Randomized Trial for Retinitis Pigmentosa</brief_title>
  <official_title>Randomized Trial for Retinitis Pigmentosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Eye Institute (NEI)</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine whether a nutritional supplement in addition to&#xD;
      vitamin A will slow the course of retinitis pigmentosa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinitis pigmentosa (RP) is a group of inherited retinal degenerations with a worldwide&#xD;
      prevalence of approximately 1 in 4,000. Patients typically report night blindness and&#xD;
      difficulty with midperipheral visual field in adolescence. As the condition progresses, they&#xD;
      lose far peripheral visual field. Most patients have reductions in central vision by age 50&#xD;
      to 80 years. Based on electroretinograms (ERGs), the course of the disease can be slowed on&#xD;
      average among adults on 15,000 IU/day of vitamin A palmitate. While conducting the trial on&#xD;
      the effects of vitamin A on RP, it became apparent that another substance in the diet could&#xD;
      be affecting the course of the disease. This prompted the present randomized, controlled&#xD;
      trial.&#xD;
&#xD;
      This study is a randomized, controlled, double-masked trial with a planned duration of 5&#xD;
      years. Patients with the common forms of RP are assigned to either a test or a control group.&#xD;
      All receive 15,000 IU/day of vitamin A palmitate in addition to the capsules under study.&#xD;
      Participants will not know the contents of the supplement or the group to which they have&#xD;
      been assigned until the end of the trial. The main outcome measurement is the total point&#xD;
      score on the Humphrey Field Analyzer (HFA). In addition, computer-averaged 30-Hz cone ERG&#xD;
      amplitudes and visual acuity are measured annually.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1996</start_date>
  <completion_date>September 1997</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Retinitis Pigmentosa</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin A</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nutritional Supplement</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Eligible patients must:&#xD;
&#xD;
          -  Be between the ages of 18 and 56&#xD;
&#xD;
          -  Be able to see the entire face of someone sitting across the table from them without&#xD;
             scanning&#xD;
&#xD;
          -  Read newspaper-size print without special magnifying aids&#xD;
&#xD;
          -  Walk unaided in daylight&#xD;
&#xD;
          -  Have a normal fasting serum vitamin A and normal liver function profile&#xD;
&#xD;
          -  Be in good general health&#xD;
&#xD;
          -  Reside in the United States&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or planning to become pregnant cannot be included because of&#xD;
             the risk of birth defects that could occur while they are on a vitamin A supplement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>56 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Eliot Berson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, Hayes KC, Johnson CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004 Sep;122(9):1297-305. doi: 10.1001/archopht.122.9.1297.</citation>
    <PMID>15364708</PMID>
  </results_reference>
  <results_reference>
    <citation>Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, Hayes KC, Johnson CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol. 2004 Sep;122(9):1306-14. doi: 10.1001/archopht.122.9.1306.</citation>
    <PMID>15364709</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 23, 1999</study_first_submitted>
  <study_first_submitted_qc>September 23, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 1999</study_first_posted>
  <last_update_submitted>September 16, 2009</last_update_submitted>
  <last_update_submitted_qc>September 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

